Differential role of MyD88 and Mal/TIRAP in TLR2-mediated gastric tumourigenesis (original) (raw)

References

1. Milne AN, Carneiro F, O’Morain C, Offerhaus GJ . Nature meets nurture: molecular genetics of gastric cancer. Hum Genet 2009; 126: 615–628.
   Article CAS PubMed PubMed Central Google Scholar
2. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789.
   Article CAS PubMed Google Scholar
3. Tye H, Kennedy CL, Najdovska M, McLeod L, McCormack W, Hughes N et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 2012; 22: 466–478.
   Article CAS PubMed Google Scholar
4. Uno K, Kato K, Atsumi T, Suzuki T, Yoshitake J, Morita H et al. Toll-like receptor (TLR) 2 induced through TLR4 signaling initiated by Helicobacter pylori cooperatively amplifies iNOS induction in gastric epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 293: 1004–1012.
   Article Google Scholar
5. Hold G, Rabkin CS, Chow WH, Smith MG, Gammon MD, Risch HA et al. A functional polymorphism of toll-like receptor 4 gene increases risk of gastric carcinoma and its precursors. Gastroenterology 2007; 132: 905–912.
   Article CAS PubMed Google Scholar
6. Tahara T, Arisawa T, Wang F, Shibata T, Nakamura M, Sakata M et al. Toll-like receptor 2 -196 to 174del polymorphism influences the susceptibility of Japanese people to gastric cancer. Cancer Sci 2007; 98: 1790–1794.
   Article CAS PubMed Google Scholar
7. Mandell L, Moran AP, Cocchiarella A, Houghton J, Taylor N, Fox JG et al. Intact gram-negative Helicobacter pylori, Helicobacter felis, and Helicobacter hepaticus bacteria activate innate immunity via toll-like receptor 2 but not toll-like receptor 4. Infect Immun 2004; 72: 6446–6454.
   Article CAS PubMed PubMed Central Google Scholar
8. Kawai T, Akira S . The role of pattern-recognition receptors in innate immunity: update on toll-like receptors. Nat Immunol 2010; 11: 373–384.
   Article CAS PubMed Google Scholar
9. Hoebe K, Jiang Z, Tabeta K, Du X, Georgel P, Crozat K et al. Genetic analysis of innate immunity. Adv Immunol 2006; 91: 175–226.
   Article CAS PubMed Google Scholar
10. Yamamoto M, Sato S, Hemmi H, Sanjo H, Uematsu S, Kaisho T et al. Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4. Nature 2002; 420: 324–329.
    Article CAS PubMed Google Scholar
11. Santos-Sierra S, Deshmukh SD, Kalnitski J, Küenzi P, Wymann MP, Golenbock DT et al. Mal connects TLR2 to PI3Kinase activation and phagocyte polarization. EMBO J 2009; 28: 2018–2027.
    Article CAS PubMed PubMed Central Google Scholar
12. Cole LE, Laird MH, Seekatz A, Santiago A, Jiang Z, Barry E et al. Phagosomal retention of Francisella tularensis results in TIRAP/Mal-independent TLR2 signaling. J Leukoc Biol 2010; 87: 275–281.
    Article CAS PubMed Google Scholar
13. Kenny EF, Talbot S, Gong M, Golenbock DT, Bryant CE, O’Neill LA . MyD88 adaptor-like is not essential for TLR2 signaling and inhibits signaling by TLR3. J Immunol 2009; 183: 3642–3651.
    Article CAS PubMed Google Scholar
14. Arbibe L, Mira JP, Teusch N, Kline L, Guha M, Mackman N et al. Toll-like receptor 2-mediated NF-kappa B activation requires a Rac1-dependent pathway. Nat Immunol 2000; 1: 533–540.
    Article CAS PubMed Google Scholar
15. Shen Y, Kawamura I, Nomura T, Tsuchiya K, Hara H, Dewamitta SR et al. Toll-like receptor 2- and MyD88-dependent phosphatidylinositol 3-kinase and Rac1 activation facilitates the phagocytosis of Listeria monocytogenes by murine macrophages. Infect Immun 2010; 78: 2857–2867.
    Article CAS PubMed PubMed Central Google Scholar
16. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 2007; 317: 121–124.
    Article CAS PubMed Google Scholar
17. Rakoff-Nahoum S, Medzhitov R . Regulation of spontaneous intestinal tumorigenesis through the adaptor protein MyD88. Science 2007; 317: 124–127.
    Article CAS PubMed Google Scholar
18. Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C . Modulation of the intestinal microbiota alters colitis-associated colorectal cancer susceptibility. PLoS One 2009; 4: e6026.
    Article PubMed PubMed Central Google Scholar
19. Swann JB, Vesely M, Silva A, Sharkey J, Akira S, Schreiber RD et al. Demonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis. Proc Natl Acad Sci USA 2008; 105: 652–656.
    Article CAS PubMed PubMed Central Google Scholar
20. Coste I, Le Corf K, Kfoury A, Hmitou I, Druillennec S, Hainaut P et al. Dual function of MyD88 in RAS signaling and inflammation, leading to mouse and human cell transformation. J Clin Invest 2010; 120: 3663–3667.
    Article CAS PubMed PubMed Central Google Scholar
21. Ernst M, Najdovska M, Grail D, Lundgren-May T, Buchert M, Tye H et al. STAT3 and STAT1 mediate IL-11-dependent and inflammation-associated gastric tumorigenesis in gp130 receptor mutant mice. J Clin Invest 2008; 118: 1727–1738.
    CAS PubMed PubMed Central Google Scholar
22. Jenkins BJ, Grail D, Nheu T, Najdovska M, Wang B, Waring P et al. Hyperactivation of Stat3 in gp130 mutant mice promotes gastric hyperproliferation and desensitizes TGF-beta signaling. Nat Med 2005; 11: 845–852.
    Article CAS PubMed Google Scholar
23. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol 2011; 186: 1199–1208.
    Article CAS PubMed Google Scholar
24. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM et al. MyD88-mediated signaling prevents development of adenocarcinomas of the colon: role of interleukin 18. J Exp Med 2010; 207: 1625–1636.
    Article CAS PubMed PubMed Central Google Scholar
25. Schiechl G, Bauer B, Fuss I, Lang SA, Moser C, Ruemmele P et al. Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages. J Clin Invest 2011; 121: 1692–1708.
    Article CAS PubMed PubMed Central Google Scholar
26. Hutchinson E . Tumour immunology: Differing roles for MYD88 in carcinogenesis. Nat Rev Immunol 2012; 12: 681.
    Article CAS PubMed Google Scholar
27. Grivennikov SI, Wang K, Mucida D, Stewart CA, Schnabl B, Jauch D et al. Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth. Nature 2012; 491: 254–258.
    Article CAS PubMed PubMed Central Google Scholar
28. Kennedy CL, Najdovska M, Jones GW, McLeod L, Hughes NR, Allison C et al. The molecular pathogenesis of STAT3-driven gastric tumourigenesis in mice is independent of IL-17. J Pathol 2011; 225: 255–264.
    Article CAS PubMed Google Scholar
29. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, Bateman T et al. gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 2009; 15: 91–102.
    Article CAS PubMed Google Scholar

Download references